FibroGen Fills Key Regulatory and Intellectual Property Positions.

SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--July 26, 1999--

FibroGen, Inc. today announced the appointments of Barry M. Calvarese, Vice President of Regulatory Affairs, and Leanne C. Price, Intellectual Property Counsel.

"We are very pleased that Barry and Leanne have joined FibroGen as we reach the critical transition from research to development," said Thomas B. Neff, President and CEO of FibroGen. "Both bring specific expertise which will facilitate the rapid introduction of FibroGen's innovative biomaterials in the next 18 months and the acceleration of our longer term therapeutic antifibrotic programs."

As Vice President of Regulatory Affairs, Barry Calvarese will provide strategic guidance as well as direct quality assurance activities to ensure accelerated regulatory review and approval of our products. Mr. Calvarese has more than 20 years of experience in regulatory and clinical affairs specializing in medical devices and pharmaceuticals. Mr. Calvarese previously held similar regulatory positions at Progressive Angioplasty Systems, Penederm Inc., Collagen Corporation, Advanced Surgical Intervention Inc. Mr. Calvarese graduated from the University of California, Los Angeles, receiving a B.A. and an M.S. in Public Health.

Leanne Price, J.D., will manage FibroGen's patent portfolio as well as develop and implement strategies to expand and reinforce FibroGen's intellectual property. Prior to joining FibroGen, Ms. Price was a Senior Patent Attorney at Incyte Pharmaceuticals, Inc. She previously worked with the law firm of Skjerven Morrill MacPherson Franklin and Friel in San Jose, California. Ms. Price graduated from University of California, San Diego with a B.S. in molecular biology and a B.A. in history. She received her J.D. from the University of California, Berkeley School of Law.

FibroGen is a private biotechnology company focusing on the development of novel anti-fibrotic pharmaceuticals and recombinant human collagen and gelatin biomaterials. The Company leverages its extracellular matrix biology expertise and comprehensive intellectual property portfolio with an extensive internal and external research and development effort. FibroGen's business model is driven by the near term market introduction of recombinant collagens and biosynthetic gelatins with longer term drug development programs addressing major unmet medical needs in dermal scarring, deep organ fibrosis and tissue regeneration. More information on FibroGen is available at the corporate web site http://www.fibrogen.com.